Bottom line
Is CURE a good fund? The bottom line
CURE is an actively managed leveraged & inverse ETF from Direxion.
It charges 0.94% — about $94 a year on every $10,000 invested, cheaper than 88% of leveraged & inverse funds we track.
It returned +22.9% over one year, +8.6% a year over five years, +13.6% a year over ten (as of Dec 31, 2025, per its prospectus).
With $172 million in net assets and 67 holdings, its largest position is Dreyfus (18.8%) and the top 10 make up 76.7% of the portfolio.
What stands out
- Low cost: cheaper than 88% of leveraged & inverse peers
- 5-year return beat 81% of category peers
What to watch
- Concentrated: top 10 holdings are 76.7% of assets
Updated Nov 19, 2026
What CURE invests in
The Fund seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.
"The Index is provided by S&P Dow Jones Indices (the Index Provider) and includes domestic companies from the healthcare sector, which includes the following industries: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology. The Index is one of eleven Select Sector Indexes developed and maintained in accordance with the following criteria: (1) each of the component securities in the Index is a constituent of the S&P 500 Index and (2) the Index is calculated by the Index Provider based on a proprietary modified market capitalization methodology which means that modifications may be made to the market capitalization weights of single stock concentrations in order to conform to the requirements of the Internal Revenue Code of 1986, as amended. As of December 31, 2025, the Index…
From the fund's prospectus (filed Mar 3, 2026).
CURE performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| CURE | +22.9% | +8.6% | +13.6% |
| Leveraged & Inverse median | −7.7% | −11.8% | −13.5% |
Source: Fund prospectus, as of Dec 31, 2025
What CURE costs
On a $10,000 investment, CURE's 0.94% expense ratio costs about $94 a year. The prospectus estimates $1,155 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.
CURE top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Dreyfus | 18.79% |
| 2 | Eli Lilly & Company LLY | 10.41% |
| 3 | N/a | 8.28% |
| 4 | Goldman Sachs Liq Es Fd A | 8.19% |
| 5 | Goldman Financial | 7.51% |
| 6 | Johnson & Johnson JNJ | 7.07% |
| 7 | Abbvie Inc ABBV | 5.08% |
| 8 | Unitedhealth Group Inc UNH | 4.31% |
| 9 | Merck & Company Inc MRK | 3.68% |
| 10 | N/a | 3.34% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 76.7% of the fund. See all top 25 holdings and asset mix →